Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer

BACKGROUND: We aimed to compare the efficacy and safety of irinotecan/S-1 (IRIS) therapy with S-1 monotherapy in patients with gemcitabine-refractory pancreatic cancer. METHODS: Patients were treated with oral S-1 (80–120 mg for 14 days every 4 weeks) plus intravenous irinotecan (100 mg m(−2) on day...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Cancer
Päätekijät: Ioka, T, Komatsu, Y, Mizuno, N, Tsuji, A, Ohkawa, S, Tanaka, M, Iguchi, H, Ishiguro, A, Kitano, M, Satoh, T, Yamaguchi, T, Takeda, K, Kida, M, Eguchi, K, Ito, T, Munakata, M, Itoi, T, Furuse, J, Hamada, C, Sakata, Y
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2017
Aiheet:
Clinical Study
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5318973/
https://ncbi.nlm.nih.gov/pubmed/28081543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.436
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia